

## BICO' Capital Markets Day 2024: Launch of BICO's Updated strategy, BICO 2.0

**BICO's updated strategy, BICO 2.0, will be presented today during the Capital Markets Day held at the company's head office in Gothenburg, between 1-4pm CEST. During the Capital Markets Day BICO will present new business areas, launch a new vision and mission as well as reiterating the company's financial targets.**

*"Today is an important day for the Group since we are entering a new phase by launching our updated strategy, BICO 2.0. Our focus ahead is clear: we will enable and automate the life science lab of the future. The new business area structure, our strategic priorities, and commercial focus areas will support us in achieving our reiterated financial targets,"* says Maria Forss, President and CEO, BICO Group AB.

### **Presentation and live stream for BICO's Capital Markets Day 2024**

BICO's President and CEO Maria Forss will together with CFO Jacob Thordenberg present the company's updated strategy, BICO 2.0 including the updates presented in this press release. In addition, a deep dive within lab automation will be presented. The Capital Markets Day ends with a Q&A.

**If you wish to watch live between 1-4pm CEST on September 17:** Register via this link: <https://ir.financialhearings.com/bico-capital-markets-day-2024/register>

**If you wish to download the presentation from the Capital Markets Day:** please visit [bico.com](https://www.bico.com)

**If you wish to watch the presentation after the Capital Markets Day:** please visit [bico.com](https://www.bico.com)

### **For further information, please contact:**

Maria Forss, President & CEO, BICO Group AB

Phone: EA Isabella Lundin +46 73 515 99 64

E-mail: [mf@bico.com](mailto:mf@bico.com)

Jacob Thordenberg, Chief Financial Officer, BICO Group AB

Phone: +46 73 534 88 84

E-mail: [jt@bico.com](mailto:jt@bico.com)

*The information was submitted for publication, through the agency of the contact persons set out above, on September 17, 2024 at 1pm CEST.*

**BICO** is a lab automation partner and provider of selected workflows to pharma and biotech.

With 46,000+ instruments installed in over 65 countries, BICO products, software, and solutions are found in more than 3,500 laboratories, including the world's top 20 pharmaceutical companies, and have been cited in over 12,000 publications. Operating through three business areas – Lab Automation, Life Science Solutions, and Bioprinting – BICO strives towards the vision to enable and automate the life science lab of the future.

BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. [www.bico.com](https://www.bico.com)

**PRESS RELEASE**

17 September 2024 13:00:00 CEST



**Attachments**

[BICO' Capital Markets Day 2024: Launch of BICO's Updated strategy, BICO 2.0](#)